Royalty Pharma (RPRX) Projected to Post Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Royalty Pharma to post earnings of $1.18 per share and revenue of $884.84 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.27 by $0.05. The firm had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million. On average, analysts expect Royalty Pharma to post $5.29 EPS for the current fiscal year and $5.64 EPS for the next fiscal year.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $65.28 on Wednesday. Royalty Pharma has a one year low of $35.92 and a one year high of $65.50. The company’s fifty day moving average price is $59.96 and its 200-day moving average price is $52.74.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%.

Analyst Ratings Changes

RPRX has been the subject of a number of analyst reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 26th. TD Cowen boosted their price objective on Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Finally, JPMorgan Chase & Co. upped their price objective on Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and an average price target of $61.57.

Insider Buying and Selling

In other news, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the transaction, the executive vice president owned 270,401 shares of the company’s stock, valued at approximately $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 208,252 shares of company stock valued at $12,324,407. Insiders own 18.84% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.